We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Congenital Toxoplasmosis Diagnosed Early By Molecular Test

By LabMedica International staff writers
Posted on 22 Sep 2011
A molecular test has been validated as a method to affirm the diagnosis of congenital toxoplasmosis (CT) using neonatal peripheral blood.

A polymerase chain reaction (PCR) assay was found to be a sensitive, rapid, and cost-effective method to affirm the diagnosis of previously undiagnosed congenital toxoplasmosis using blood from very young infants.

Scientists at the University of Montpellier I (France) prospectively enrolled all successive neonates who had blood sampled for molecular diagnosis of CT before the age of three weeks from March 2003 to December 2008, in the Languedoc-Roussillon region, in southern France. More...
A series of tests were performed on amniotic fluid, placenta, and cord blood by a highly performing conventional PCR that has shown excellent sensitivity as compared with other real-time PCR assays and mice inoculation. Serologic follow-up during the first year of life for immunoglobulin (Ig) IgG, IgM, and IgA by enzyme linked immunosorbent assay (ELISA), immunofluorescence, and/or immunosorbent agglutination assay (ISAGA), and comparative immune charge relating specific IgG to total IgG.

In a cohort of 12 consecutive neonates, the PCR assay established the diagnosis of five of six cases of congenital toxoplasmosis and did so earlier than serologic methods. In all cases of CT, the maternal infection occurred in the third trimester. The PCR tests were performed using neonatal peripheral blood on day-two to day-four for eight cases, one case on day 10 and three cases on day 15. The PCR was positive in 83% of the cases of CT and negative in the remaining cases. In one neonate, the positive PCR using peripheral blood was the first test, which affirmed the diagnosis of CT. In the cohort, one false-negative molecular test was recorded, emphasizing that the diagnosis of CT is difficult and often needs a combination of laboratory tests.

The authors concluded that with a low false-negative rate and no false-positive result, PCR on neonatal peripheral blood was validated as it can be performed routinely. The assay is able to affirm the diagnosis of CT and perhaps render the first positive result. The study was published on August 8, 2011, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
University of Montpellier I



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.